SCHEMBL6156697

SCHEMBL6156697

NCc1cccc(N(NC(=O)Nc2ccc(N3CCCCC3=O)cc2)c2ccc(F)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
GLA P06280 1/20 0.47
PKM P14618 1/20 0.47
RAB9A P51151 1/20 0.47
LMNA P02545 2/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
F10 P00742 8/20 0.42
PRSS1 P07477 2/20 0.41
PRSS2 P07478 2/20 0.41
PRSS3 P35030 2/20 0.41
MAPT P10636 2/20 0.41
FPR1 P21462 1/20 0.40
FPR2 P25090 1/20 0.40
HCRTR1 O43613 1/20 0.40
KDM1A O60341 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6156447 0.97 SMN1; SMN2 (0.50) SMN1; SMN2NPC1ALDH1A1TP53GLA
SCHEMBL6156115 0.93 TSHR (0.46) SMN1; SMN2NPC1ALDH1A1TP53GLA
SCHEMBL6157131 0.92 TSHR (0.46) SMN1; SMN2NPC1ALDH1A1TP53GLA
SCHEMBL6159444 0.88 F10 (0.37) SMN1; SMN2NPC1ALDH1A1TP53GLA
SCHEMBL6156428 0.81 NPC1 (0.47) SMN1; SMN2NPC1ALDH1A1TP53GLA
SCHEMBL6156652 0.80 F10 (0.38) SMN1; SMN2NPC1TP53RAB9ALMNA
SCHEMBL6156018 0.80 S1PR1 (0.37) SMN1; SMN2LMNAHPGDTSHRMAPT
SCHEMBL6159501 0.78 SMN1; SMN2 (0.50) SMN1; SMN2NPC1ALDH1A1TP53GLA
SCHEMBL6156444 0.78 F10 (0.62) SMN1; SMN2NPC1ALDH1A1TP53GLA
SCHEMBL6158842 0.78 KMT2A (0.38) SMN1; SMN2NPC1ALDH1A1TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US claimed
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases MERCK PATENT GMBH (DE) 2005-08-04 US disclosed
EP-1501814-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GmbH (DE) 2005-02-02 EP disclosed
WO-2003093254-A1 SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES MERCK PATENT GMBH (DE) 2003-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171102-A1 Semicarbazide derivatives for combating thromboembolic diseases SERPINC1, F11, F12 SMN1; SMN2 3250/4885NPC1 1451/4885ALDH1A1 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.